Table 1.
Composition of liposomes, drug loading efficiency (DLE) and encapsulation efficiency (EE). Composition, drug loading efficiency and encapsulation efficiency of empty liposome (L), liposomes containing Everolimus (E-L), Vinorelbine (V-L), and combination of and combination of Everolimus and Vinorelbine (EV-L)
| Liposome | DOPC (mg/mL) | Cholesterol (mg/mL) |
DSPE(PEG)2000-OMe (mg/mL) | TTP (mg/mL) |
E (mg/mL) |
V (mg/mL) |
DLE (%) |
EE (%) |
|---|---|---|---|---|---|---|---|---|
| L | 3.93 | 0.965 | 0.140 | 0.452 | — | — | — | — |
| E-L | 3.93 | 0.965 | 0.140 | 0.452 | 0.397±0.001 | — | 7.2±0.01 | 99.1±0.17 |
| V-L | 3.93 | 0.965 | 0.140 | 0.452 | — | 0.189±0.008 | 3.4±0.14 | 23.6±1 |
| EV-L | 3.93 | 0.965 | 0.140 | 0.452 | 0.394±0.005 | 0.192±0.01 | 7.29±0.1(E), 3.5±0.34 (V) |
98.5±1.2 (E), 24±1.3 (V) |
Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DSPE-PEG2000-OMe, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt); TTP, tumor targeting peptide; E, Everolimus; V, Vinorelbine; DLE, drug loading efficiency; EE, encapsulation efficiency.